肿瘤药学Issue(4)：293-296,4.DOI:10.3969/j.issn.2095-1264.2013.071
培美曲塞与多西他赛分别联合顺铂治疗晚期非小细胞肺癌的疗效观察
Observation on the Clinical Efficacy of Pemetrexed and Docetaxel, Respectively Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer
麻青 1张军峰 1李建军 1白琴霞 1刘艳棠1
作者信息
- 1. 鹤壁市人民医院肿瘤内科，河南 鹤壁，458030
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy and safety of pemetrexed and docetaxel respectively combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods 95 patients with advanced non-small cell lung cancer were selected and randomly divided into two groups. 48 patients in the pemetrexed group were given intravenous infusion of pe-metrexed 500 mg·m-2 at d1, and intravenous infusion of cisplatin 25 mg·m-2 at d1 ~ d3; 47 patients in the docetaxel group were given intravenous infusion of docetaxel 75 mg·m-2 at d1 and d8, and intravenous infusion of cisplatin 25 mg·m-2 at d1~ d3. Three weeks’treatment was taken as a cycle, and the clinical efficacy and incidence of adverse reactions were observed and compared after every two cycles’treatment. Results The overall response rates of pemetrexed group and docetaxel group were respectively 22.92% and 17.02%, and the disease control rates were respectively 52.08% and 46.81%; there was no significant difference be-tween the two groups (P>0.05). However, the incidence rates of adverse reactions such as leukopenia, anemia, thrombocytope-nia, nausea and vomiting, liver dysfunction in pemetrexed group was significantly lower than that in the docetaxel group (P<0.01). Conclusion Pemetrexed combined with cisplatin had equal efficacy as but less adverse reactions than docetaxel combined with cisplatin in the treatment of non-small cell lung cancer.关键词
培美曲塞/多西他赛/顺铂/晚期非小细胞肺癌Key words
Pemetrexed/Docetaxel/Cisplatin/Advanced Non-small cell lung cancer分类
医药卫生引用本文复制引用
麻青,张军峰,李建军,白琴霞,刘艳棠..培美曲塞与多西他赛分别联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].肿瘤药学,2013,(4):293-296,4.
